News release

Notice of press release from Nagoya University

Nagoya University and Chulalongkorn University, Collaboration in Thailand
Successful treatment of malignant lymphoma using non-viral vector-based CAR-T cells

Nagoya University has issued a press release regarding the results of clinical research using CAR-T cells at Chulalongkorn University in Thailand.

A research team led by Professor Yoshiyuki Takahashi in the Department of Pediatrics, Nagoya University Graduate School of Medicine and designated lecturer Nobuhiro Nishio in the Department of Advanced Medicine have developed a chimeric antigen receptor gene-modified T cell (CAR-T cell) therapy employing the piggyBac transposon method.
Using this culture method, clinical trials for acute lymphocytic leukemia and malignant lymphoma have been conducted at Chulalongkorn University Hospital in Thailand since 2020 with the support of Nagoya University. Recently, it was reported that it was effective in treating 5 patients with malignant lymphoma.
The press release also reported that Nagoya University plans to start an investigator-initiated clinical trial using CAR-T cells for malignant lymphoma in Japan. J-TEC plans to manufacture the CAR-T cells used for investigator-initiated clinical trials in Japan.

For details, please see the announcement from Nagoya University below.

News Release from Nagoya University
Nagoya University and Chulalongkorn University, Collaboration in Thailand
Successful treatment of malignant lymphoma using non-viral vector-based CAR-T cells

J-TEC aims to commercialize CAR-T cell therapy technology in collaboration with Nagoya University in Japan

As a top runner in regenerative medicine in Japan, we obtained approval to manufacture and sell autologous cultured epidermis in 2007, the first regenerative medicine product in Japan.
We commercialized autologous cultured cartilage (orthopedic field) in 2013, autologous cultured corneal epithelium (ophthalmology field) in 2020, and autologous cultured oral mucosal epithelium (ophthalmology field) in 2021. On March 17, 2023, we also obtained manufacturing and marketing approval for our fifth product, autologous cultured epidermis maintaining melanocytes for the treatment of vitiligo.
Utilizing the experience and know-how we have cultivated as a platform provider for autologous regenerative medical products, we will accelerate the flow of industry-academia collaboration in commercializing seeds from Japanese universities.
In collaboration with Nagoya University, we will continue to work on commercialization and practical application of the autologous CAR-T cell therapy technology in Japan, and contribute to improving the quality of life (QOL) of patients.

Reference

J-TEC News Release (June 18, 2018)

Japan Tissue Engineering, Nagoya University, and Shinshu University sign patent license agreement for the development of a low-cost manufacturing technology for autologous CAR-T cell therapy with enhanced targeting efficiency against CD 19-positive acute lymphoblastic leukemia